Familial Myeloproliferative Disorders

Status Completed

Clinical Trial Summary

Myeloproliferative disorders occur in families, thus giving rise to the theory that it is a genetic disease that may be caused by an abnormal gene in the DNA that can be passed from one generation of family members to another. DNA can be gathered from family members through blood samples and the investigators will investigate (through DNA testing) to see if there are abnormal genes that may be responsible for causing the MPDs. Understanding which genes are responsible for causing MPDs can help develop ways to identify people who may be at risk for developing an MPD, allow for the development of better treatments, possibly a cure, or even prevent the development of MPDs.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00666289
Study type	Observational
Source	Icahn School of Medicine at Mount Sinai
Contact
Status	Completed
Phase	N/A
Start date	March 2008
Completion date	June 20, 2015

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05558696` - A Study of Bomedemstat (MK-3543) in Participants With Polycythemia Vera (MK-3543-004)	Phase 2
Active, not recruiting	`NCT03289910` - Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia	Phase 2
Completed	`NCT02912884` - Treatment of Polycythaemia Vera and Essential Thrombocythaemia: Influence on the Clot Structure
Recruiting	`NCT02897297` - Myeloproliferative Neoplastic Diseases Observatory From Brest
Completed	`NCT01949805` - Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera	Phase 3
Completed	`NCT00666549` - Research Tissue Bank
Completed	`NCT00241241` - Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera	Phase 2
Completed	`NCT00052520` - Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation	Phase 1/Phase 2
Active, not recruiting	`NCT05485948` - A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU	Phase 2
Completed	`NCT01588015` - Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant	Phase 1
Completed	`NCT01243944` - Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)	Phase 3
Recruiting	`NCT05481151` - A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV	Phase 3
Recruiting	`NCT05031897` - Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant	Phase 2
Recruiting	`NCT04116502` - MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera	Phase 3
Completed	`NCT01901432` - A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera	Phase 1/Phase 2
Active, not recruiting	`NCT04262141` - IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)	Phase 2
Not yet recruiting	`NCT05566535` - Changes in QoL and Symptoms in Patients With Polycythemia Vera Receiving Ruxo in a Routine Clinical Practice
Active, not recruiting	`NCT04057040` - Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)	Phase 2
Completed	`NCT03907436` - The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase	N/A
Completed	`NCT01981850` - A Phase 2 Study of RO7490677 In Participants With Myelofibrosis	Phase 2